Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Perspective Therapeutics Announces Collaboration Agreement Qith Bristol Myers Squibb To Evaluate [(212)Pb]VMT01 In Combination With Nivolumab In MC1R-Positive Metastatic Melanoma; Perspective Will Sponsor And Fund The Combination Study And Bristol Myers Squibb Will Provide Nivolumab For Use In The Study.

Author: Benzinga Newsdesk | March 18, 2024 08:06am

Posted In: BMY CATX